Skip to contentZ
Zivo Bioscience, Inc.
Z
ZIVOZivo Bioscience, Inc. Q3 2023 · 10-Q
Revenue$11.80K$11.80K— vs Q3 2022 Net Income-$1.82M-$1.82MN/M vs Q3 2022 EPS, diluted—
Operating Income-$1,572,388N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Zivo Bioscience, Inc. · CIK 1101026 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,969,520N/M Margins · derivedGross margin35.0%
Operating margin-13325.3%
Net margin-15465.4%
ended Sep 30, 2023 · filed Nov 13, 2023 · 44 d after period end